Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

Analysis of Liquidity Ratios

Microsoft Excel

Liquidity Ratios (Summary)

Pfizer Inc., liquidity ratios

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Current ratio 0.91 1.22 1.40 1.35 0.88
Quick ratio 0.50 0.80 1.00 0.78 0.50
Cash ratio 0.27 0.54 0.73 0.47 0.26

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Pfizer Inc. current ratio deteriorated from 2021 to 2022 and from 2022 to 2023.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Pfizer Inc. quick ratio deteriorated from 2021 to 2022 and from 2022 to 2023.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Pfizer Inc. cash ratio deteriorated from 2021 to 2022 and from 2022 to 2023.

Current Ratio

Pfizer Inc., current ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Current assets 43,333 51,259 59,693 35,067 32,803
Current liabilities 47,794 42,138 42,671 25,920 37,304
Liquidity Ratio
Current ratio1 0.91 1.22 1.40 1.35 0.88
Benchmarks
Current Ratio, Competitors2
AbbVie Inc. 0.87 0.96 0.79 0.84 3.18
Amgen Inc. 1.65 1.41 1.59 1.81 1.44
Bristol-Myers Squibb Co. 1.43 1.25 1.52 1.58 1.60
Eli Lilly & Co. 0.94 1.05 1.23 1.40 1.16
Gilead Sciences Inc. 1.43 1.29 1.27 1.40 3.10
Johnson & Johnson 1.16 0.99 1.35 1.21 1.26
Merck & Co. Inc. 1.25 1.47 1.27 1.02 1.24
Regeneron Pharmaceuticals Inc. 5.69 5.06 3.56 3.63 3.67
Thermo Fisher Scientific Inc. 1.75 1.48 1.50 2.13 1.92
Vertex Pharmaceuticals Inc. 3.99 4.83 4.46 4.33 3.61
Current Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 1.26 1.28 1.36 1.36 1.56
Current Ratio, Industry
Health Care 1.15 1.17 1.22 1.22 1.34

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Current ratio = Current assets ÷ Current liabilities
= 43,333 ÷ 47,794 = 0.91

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Pfizer Inc. current ratio deteriorated from 2021 to 2022 and from 2022 to 2023.

Quick Ratio

Pfizer Inc., quick ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Cash and cash equivalents 2,853 416 1,944 1,784 1,305
Short-term investments 9,837 22,316 29,125 10,437 8,525
Trade accounts receivable, less allowance for doubtful accounts 11,177 10,952 11,479 7,930 8,724
Total quick assets 23,867 33,684 42,548 20,151 18,554
 
Current liabilities 47,794 42,138 42,671 25,920 37,304
Liquidity Ratio
Quick ratio1 0.50 0.80 1.00 0.78 0.50
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc. 0.63 0.69 0.56 0.60 2.91
Amgen Inc. 0.99 0.95 1.06 1.30 1.01
Bristol-Myers Squibb Co. 1.04 0.87 1.20 1.28 1.26
Eli Lilly & Co. 0.52 0.63 0.80 0.85 0.68
Gilead Sciences Inc. 1.06 0.99 0.95 1.08 2.86
Johnson & Johnson 0.82 0.71 1.04 0.91 0.94
Merck & Co. Inc. 0.68 0.93 0.73 0.58 0.78
Regeneron Pharmaceuticals Inc. 4.82 4.16 2.98 2.86 2.81
Thermo Fisher Scientific Inc. 1.27 1.06 1.00 1.63 1.19
Vertex Pharmaceuticals Inc. 3.60 4.46 4.04 4.02 3.33
Quick Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.84 0.90 0.98 0.96 1.18
Quick Ratio, Industry
Health Care 0.84 0.87 0.90 0.91 1.01

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 23,867 ÷ 47,794 = 0.50

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Pfizer Inc. quick ratio deteriorated from 2021 to 2022 and from 2022 to 2023.

Cash Ratio

Pfizer Inc., cash ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Cash and cash equivalents 2,853 416 1,944 1,784 1,305
Short-term investments 9,837 22,316 29,125 10,437 8,525
Total cash assets 12,690 22,732 31,069 12,221 9,830
 
Current liabilities 47,794 42,138 42,671 25,920 37,304
Liquidity Ratio
Cash ratio1 0.27 0.54 0.73 0.47 0.26
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc. 0.34 0.31 0.28 0.30 2.56
Amgen Inc. 0.60 0.59 0.66 0.91 0.69
Bristol-Myers Squibb Co. 0.55 0.42 0.78 0.83 0.84
Eli Lilly & Co. 0.11 0.13 0.26 0.29 0.21
Gilead Sciences Inc. 0.64 0.57 0.56 0.65 2.50
Johnson & Johnson 0.50 0.42 0.70 0.59 0.54
Merck & Co. Inc. 0.28 0.54 0.34 0.30 0.47
Regeneron Pharmaceuticals Inc. 3.17 2.46 1.45 1.33 1.53
Thermo Fisher Scientific Inc. 0.58 0.50 0.33 1.00 0.39
Vertex Pharmaceuticals Inc. 3.16 3.93 3.51 3.55 2.85
Cash Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.46 0.51 0.59 0.58 0.81
Cash Ratio, Industry
Health Care 0.44 0.49 0.52 0.54 0.64

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 12,690 ÷ 47,794 = 0.27

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Pfizer Inc. cash ratio deteriorated from 2021 to 2022 and from 2022 to 2023.